Article

Advancing Innovation in Cancer Care - Bringing the Next Wave of Oncology Products to Market

The rapid pace of innovation in oncology was displayed at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, where research highlighted promising developments, including advances in immunotherapy and targeted therapies for rare cancers.

Scientific breakthroughs, including cell and gene therapies (CGT), personalized cancer vaccines, and targeted therapies, have helped to redefine approaches for certain cancers, contributing to the substantial progress achieved in five-year relative survival rates for many cancer types.

See how experts Tommy Bramley and Eric Monzon discuss the next wave of cancer care. To continue reading this article, please visit PharmExec.com

Related resources

People Sitting On Chairs In Seminar

Article

RAPS Convergence 2025: Transparency, Trust, and Resilience in Regulatory Science
Business

Article

The complex path to meeting promotional materials requirements in Europe
Data Analytics Banner

Article

The critical role of industry in the PMS and master data

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.